StockData
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

MoonLake Immunotherapeutics

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$9.75+0.20 (+2.09%)

Close on Oct 19, 2026

Market cap
$720.67M
P/E (TTM)
–
Dividend yield
–

MoonLake Immunotherapeutics revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

MoonLake Immunotherapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.